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QUESTION ASKED: Is it feasible and acceptable, and
what level of compliance is achieved when asking
oncology patients to regularly self-report both ad-
verse events (Patient-Reported Outcomes version of
the Common Terminology Criteria for Adverse Events
[PRO-CTCAE]) and health-related quality of life
(HRQOL) at home on an electronic system (Internet/
telephone option)?
SUMMARY ANSWER: High compliance was observed
for weekly patient self-reported PRO-CTCAE plus
HRQOL completions every 4 weeks. Patient feedback
was positive, highlighting a willingness to complete
questionnaires, with the system being easy to use and
problem free.
WHAT WE DID: Two hundred forty-nine oncology pa-
tients receiving a variety of treatments from 2 United
Kingdom hospitals were sent weekly auto-reminders to
complete PRO-CTCAE and every 4 weeks, the HRQOL
was also available. These self-reported questionnaires
were completed online or via a telephone-based in-
teractive voice response system (IVRS) for a 12-week
period.
WHAT WE FOUND: Overall compliance was more than
60% at each individual timepoint and the cumulative
compliance was 75% to 80% for each questionnaire.
Some differences were observed across the treatment
groups (chemotherapy higher compliance), patient age
(older patients completed the PRO-CTCAE more often),
and choice of system (greater HRQOL completion with
IVRS). The Internet option was more popular (82.3%)
and quicker, but some older patients (16.9%) pre-
ferred the IVRS. Most participants remained on the
study throughout the 12-week period, with only 13
active withdrawals, 6 deaths, and 18 passive with-
drawals (not completing any electronic question-
naires postbaseline).
BIAS, CONFOUNDING FACTORS: This feasibility study
was carried out in a general oncology setting in a hy-
pothetical trial scenario, rather than among active
clinical trial participants. This influenced how the
study was presented and some of the practicalities
(baseline completion was defined flexibly rather than
stringently as per clinical trial protocols), and poten-
tially affected uptake and compliance. The recruit-
ment rate was relatively low; therefore, there may be
biases as a result of self-selection.
REAL-LIFE IMPLICATIONS: The value of routine PRO
collection is increasingly recognized in cancer clinical
trials, and the need for innovative methods to achieve
this remotely have been heightened further during and
after the coronavirus disease 2019 pandemic. Our
findings highlight the willingness of patients to self-
report from home and the acceptability of the elec-
tronic system. Additional exploration of this system
within active clinical trials is warranted to explore
whether implementation can improve the precision
and accuracy of adverse event reporting, leading to
improved data quality and patient safety.
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abstract
PURPOSE Adverse event (AE) reporting is essential in clinical trials. Clinician interpretation can result in under-
reporting; therefore, the value of patient self-reporting has been recognized. The National Cancer Institute
has developed a Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
(PRO-CTCAE) for direct patient AE reporting. A nonrandomized prospective cohort feasibility study aimed to
explore the compliance and acceptability of an electronic (Internet or telephone) system for collecting patient
self-reported AEs and quality of life (QOL).
METHODS Oncology patients undergoing treatment (chemotherapy, targeted agents, hormone therapy, ra-
diotherapy, and/or surgery) at 2 hospitals were sent automated weekly reminders to complete PRO-CTCAE once
a week and QOL (for amaximum of 12 weeks). Patients had to speak/understand English and have access to the
Internet or a touch-tone telephone. Primary outcome was compliance (proportion of expected questionnaires),
and recruitment rate, attrition, and patient/staff feedback were also explored.
RESULTS Of 520 patients, 249 consented (47.9%)—mean age was 62 years, 51% were male, and 70% were
married—and 230 remained on the study at week 12. PRO-CTCAE was completed at 2,301 (74.9%) of 3,074
timepoints and QOL at 749 (79.1%) of 947 timepoints. Individual weekly/once every 4 weeks compliance
reduced over time but was more than 60% throughout. Of 230 patients, 106 (46.1%) completed 13 or more
PRO-CTCAE, and 136 (59.1%) of 230 patients completed 4 QOL questionnaires. Most were completed on the
Internet (82.3%; mean age, 60.8 years), which was quicker, but older patients preferred the telephone option
(mean age, 70.0 years). Positive feedback was received from patients and staff.
CONCLUSION Self-reporting of AEs and QOL using an electronic home-based system is feasible and acceptable.
Implementation of this approach in cancer clinical trials may improve the precision and accuracy of AE
reporting.
JCO Oncol Pract 16. © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License.
INTRODUCTION
As more cancer treatments with innovative modes of
action are evaluated via clinical trials, the need to
monitor and record adverse events (AEs)1 increases to
ensure safety and guide prescribing and patient in-
formation.2 The Common Terminology Criteria for
Adverse Events (CTCAE)3 is the standard method of
reporting AEs, allowing clinicians to uniformly classify
AEs and their severity, but its focus is on safety rather
than exploring patient experiences.4 Clinician in-
terpretation can result in under-reporting of lower-
grade morbidity and severity downgrading2,5,6; therefore,
patient self-reporting is a complementary alternative.7,8
The CTCAE system is suitable for acute AEs when
patients receive regular oncologist review; however,
many new treatments are outpatient-based oral ther-
apies that require less frequent reviews. Although these
treatments do not result in the acute severe AEs ob-
served with chemotherapy, they often result in low- to
moderate-grade prolonged symptoms that significantly
impact patients’ lives and treatment adherence.1,9
CTCAE is less appropriate for monitoring AEs during
these treatments.7
Patient-reported outcomes (PROs) enable system-
atic, subjective measurement of symptoms and ex-
periences. Health-Related Quality of Life (HRQOL)
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questionnaires are well-established PRO measures used in
phase II and III randomized clinical trials.10 Implementing
PROs to routinely monitor individual patients’ AEs is rela-
tively uncommon, despite accumulating evidence dem-
onstrating improvement in communication, patient well-
being, symptom control, and survival when clinicians re-
ceive these data.11-14
The National Cancer Institute developed the Patient-
Reported Outcome version of the CTCAE item bank
(PRO-CTCAE) to obtain direct patient AEs in trials.15
Technology can help PRO-CTCAE to become a standard-
ized trial approach,15,16 andWeb-based PRO efficiency and
patient acceptability has been demonstrated.17,18 Of the
United Kingdom population, 90% are regular Internet
users; however, 24% of those age 65 years and older re-
ported no Internet use in the past 3 months.19 Therefore,
a telephone interactive voice response system (IVRS)
widens eligibility.
Oncology clinicians, trialists, the pharmaceutical industry,
and regulatory authorities recognize the importance of col-
lecting PRO data in drug development and evaluation.1,10,20,21
Concerns still exist about potential patient burden and data
collection frequency.22 There is a pressing need to develop
robust systems to collect PRO-CTCAE alongside clinician-
reported CTCAE, as well as explore the feasibility of collecting
frequent PRO-CTCAE in addition to HRQOL at prespecified
trial timepoints where QOL is an important primary or sec-
ondary outcome.
This feasibility study evaluated a self-reported electronic
system—Internet/IVRS—to collect PRO-CTCAE and HRQOL
in a mixed group of oncology patients and to combine the
data with a standard clinical trial database. Primary outcome
was compliance and secondary outcomes included re-
cruitment rates, Internet/IVRS uptake, attrition, patient and
staff feedback, and system testing.
METHODS
Patient Population and Study Design
This proof-of-principle, nonrandomized, prospective, co-
hort feasibility study was conducted in 2 United Kingdom
hospitals between August 19, 2014, and October 7, 2015,
with 12-week follow-up. The study design modeled a hy-
pothetical clinical trial scenario in which PRO-CTCAE data
are collected for safety (real time, as frequently as needed)
and HRQOL at predefined timepoints to assess treatment
outcomes.
Our aim when defining the study population was to capture
a range of patients across the main cancer sites and
treatments. We anticipated that this would increase the
generalizability of the findings. Consecutive eligible patients
were approached. Therefore, the sample target was 210
participants with early or metastatic cancer receiving either
chemotherapy, targeted agents, hormone therapy, radio-
therapy, or surgery (42 patients per group, allowing for
30% attrition),23 plus 42 patients with Eastern Cooperative
Oncology Group (ECOG) performance status score of 2 to 3
receiving any treatment. Eligibility criteria included speaking/
understanding English and access to a touch-tone telephone
and/or Internet. Patients on clinical trials with regular HRQOL
assessments were excluded. Written informed consent was
obtained from study participants. Ethical approval was
granted from the National Health Service Leeds-East Re-
search Ethics Committee (14.YH.0181).
Study Outcomes
• Compliance was defined as the proportion of completed
questionnaires out of expected completions. This was
calculated cumulatively for each questionnaire—PRO-
CTCAE and HRQOL—and at each expected timepoint
weekly (7-day window)/every 4 weeks (28-day window)
across gender, system, study group, and age. Multiple
completions per week were discounted from compli-
ance calculations. The number of completions per
participant was also calculated, including multiple
completions.
• Recruitment rate was defined as the proportion of
patients who consented to the study relative to eligible
patients approached. Demographics—age, gender,
diagnosis, and treatment—were compared between
consenting patients and declining patients.
• Internet/IVRS uptake was calculated in 2 ways: the
proportion who preferred each system at baseline and
the proportion who used each system most often
during the study.
• Active withdrawal was the predominant attrition out-
come, defined as the proportion of participants who
actively requested withdrawal from the study out of
participants who consented. Any withdrawal reasons
were recorded where provided. In addition, passive
withdrawal was defined as the proportion of partici-
pants who did not complete any electronic question-
naires postbaseline but did not request withdrawal.
Passive withdrawals are included in the compliance
calculations, but active withdrawals were excluded
after the withdrawal date.
• Patient and staff feedback was captured on a paper
end-of-study (EOS) questionnaire that explored ex-
periences of the system(s) and staff views.
• System testing was assessed through the documen-
tation of system issues and phone calls and comments
from patients and staff. Call and online session time
logs were also recorded.
Electronic System and Questionnaires
Participant registration via the clinical trials research unit
(CTRU) registration system provided the trial number and
username and password for accessing the electronic system
to complete the 2 self-reported questionnaires.
First, 21 PRO-CTCAE items15 covering 11 common symp-
toms (pain and/or discomfort, nausea, vomiting, diarrhea,
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constipation, headache, mouth/throat sores, fatigue, skin
rash, flu-like symptoms, and muscle ache) were available at
any time. Second, the European Organization for the Re-
search and Treatment of Cancer Quality of Life Questionnaire
C30 (EORTC-QLQ-C30) 30-item cancer-specific measure
exploring HRQOL24 was available once every 4 weeks.
Holch et al25 provide a detailed overview of the Internet
(QTool) system. Internet system users were presented with 1
(PRO-CTCAE) or 2 questionnaires (if EORTC-QLQ-C30 was
due). The IVRS that was developed specifically for this study
by CTRU technicians was a freephone number. To ease the
log-in process on the IVRS, all usernames were a 5-digit
numerical code, and passwords were a 4-digit numerical
code. The same format was used on the Internet system to
enable participants to switch between systems if required.
Once logged in, IVRS users heard a welcomemessage, then
heard the EORTC-QLQ-C30 questionnaire (if due, every 4
weeks) and/or the PRO-CTCAE. Each question was read out,
followed by the response options (eg, “Question number 13.
In the last 7 days, what was the SEVERITY of your fatigue,
tiredness, or lack of energy at its worst? Press 1 then hash for
none, 2 then hash for mild, 3 then hash for moderate.…”)
Patients could interrupt the responses with their selected
response and could take a break—hang up and re-ring—
after the first questionnaire if needed.
A specific application pulled the data from a separate server
that held the Internet/QTool data, which was then stored in
a specific PRO database on CTRU servers. A program was
created to generate/send automated reports to the local
research team detailing completions. The PRO database
was combined with the standard trial database (Elsevier's
MACRO Data Capture System) that contained all the par-
ticipant clinical record forms for statistical analysis.
Procedure
Eligible patients were initially approached by clinical/re-
search staff with the study information sheet. Recruitment
was undertaken sequentially across the treatment sub-
groups and stopped once each prespecified target number
was reached.
Demographic details and computer use (frequency and
perceived confidence) were self-reported at baseline.
Clinical data captured from medical records included di-
agnosis, treatment, ECOG performance status, and treat-
ment changes (discontinuation/new treatments). Baseline
electronic questionnaires were completed in clinic, or
a brief demonstration was provided and the full ques-
tionnaires completed at home on the preferred system. All
participants received step-by-step instructions covering
both systems. Participants were reminded (by automated
e-mail, text, or both) weekly—every 7 days from the reg-
istration date—for 12 weeks to complete the electronic
questionnaires. EOS paper questionnaires were sent/given
once each participant had completed the 12 weeks.
Any deaths or withdrawal requests were actioned promptly
(reminders stopped). All participants were reminded that
the system was not intended to replace usual care or
methods of reporting any symptoms or concerns to their
clinical team. However, researchers endeavored to attach
a paper report summarizing any recent AEs to participants’
medical notes at any scheduled outpatient visits.
Analysis
Data analysis was performed using STATA between August
2016 and February 2017. Descriptive analysis of the study
outcomes was conducted. Missing data were not imputed.
System issues were coded thematically into generic and
patient issues.
RESULTS
Study Population
Of 888 patients who were assessed for eligibility during the
study period, 368 were ineligible, and of 520 approached,
249 consented to the study (recruitment rate 47.9%; Fig 1).
Consent rates were higher in targeted agents (57 of 93;
61.3%) and chemotherapy groups (49 of 97; 50.5%), and
lower in surgery (42 of 91; 46.2%), radiotherapy (47 of
107; 43.9%), and hormone therapy (54 of 132; 40.9%;
x2 5 10.3; P 5 .04).
Participants (mean age, 62.1 years; standard deviation
[SD], 13.3 years) were significantly younger than those
who declined (mean age, 69.4 years; SD 5 12.3 years;
t5 26.5; df 5 518; P, .001). No differences were found
by gender (P 5 .46) or disease site (P 5 .08). Of 271 who
declined, reasons included being too busy (n 5 56;
20.7%), not interested (n 5 26; 9.6%), and being too
worried/stressed (n 5 15; 5.5%). Access to the required
technology prevented participation for 21 non-Internet
users (who did not want to use IVRS; 7.7%), 15 patients
who were hard of hearing (5.5%), and 5 who were unskilled
and/or disliked both options (1.8%).
Table 1 lists the demographic and clinical characteristics of
the sample. This shows almost similar numbers of male and
female patients (n 5 128, 51.4%; and n 5 121, 48.6%,
respectively), and most were married (n 5 173; 69.5%)
and 124 were retired (49.8%). Breast (n 5 57; 22.9%),
colorectal (n 5 39; 13.7%), and prostate (n 5 33; 13.3%)
cancer were the most common cancer types. IVRS par-
ticipants were older (mean age, 70.0 years; SD, 9.9 years;
Internet mean age, 60.8 years; SD, 13.7 years), had lower
education levels, and more had prostate cancer (12 of 43;
27.9%) compared with Internet users.
Internet/IVRS Uptake
At baseline, 82.3% of participants (205 of 249) indicated
they preferred the Internet, whereas 16.9% (42 of 249)
preferred the IVRS (1 had no preference and 1 withdrew
before registration). Most participants used their preferred
system throughout the study period, but a few used both
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No. formally enrolled in the study
at 12-week point excluding active
withdrawals and deaths
(n = 230) 
Completed week 12 PRO-CTCAE electronic 
questionnaire
 (n = 155)
Completed EOS questionnaire feedback
(n = 192 of 232)† 
 Completed baseline questionnaires,
including both electronic questionnaires
(n = 229) 
Consented to REPORT-UK study
Eligible participants, 47.9%                      (n = 249) 
Eligible
(n = 520)
Assessed for eligibility
(N = 888)
Did not complete either electronic                     (n = 7)
   questionnaires at baseline 
Did not complete both electronic                     (n = 20)  
   questionnaires at baseline  
      PRO-CTCAE                                                  (n = 17) 
      EORTC-QLQ-C30                                          (n = 10)
Declined                               (n = 271)
No reason given                   (n = 57)
Too busy                                (n = 56)
Not interested                       (n = 26)
No Internet and said             (n = 21)
   no to using phone
Did not want to                     (n = 19)
   do research
Hard of hearing                     (n = 15) 
Too worried                               (n = 15)
Taken part in other research    (n = 12)
Too ill                                         (n = 11)
Other                                          (n < 10)
Ineligible                                                             (n = 368)
Did not receive eligible treatment                   (n = 77)
Eligible treatment group already filled           (n = 65)
Discharged                                                        (n = 53)
Advised not appropriate to approach             (n = 40)
Histology not eligible                                        (n = 36)
No Internet and no land line phone                (n = 19)
Timing/identified too late                                 (n = 19)
Patient died                                                       (n = 20)
   (after being given PIS [n = 4])
Enrolled in another study                                 (n = 15)
Performance status/not ECOG PS 2/3 when only
recruiting this group                                         (n = 11)
Language barrier                                                (n = 8)
Out of area                                                           (n = 5)
Passive withdrawers*
Did not complete any electronic                   (n = 18) 
   questionnaires postbaseline
Did not complete any PRO-CTCAE               (n = 19)
   questionnaires postbaseline 
Did not complete any EORTC-QLQ-C30       (n = 35) 
   questionnaires postbaseline
Active withdrawal requests                            (n = 13)
Week 0                                                              (n = 5)
Week 1                                                              (n = 2) 
Week 2                                                              (n = 2) 
Week 3                                                              (n = 1) 
Week 4                                                              (n = 2)  
Week 10                                                            (n = 1) 
Patient died                                                             (n = 6)
FIG 1. Study recruitment CONSORT
diagram. (*) Passive withdrawers
are those who did not complete the
online questionnaires postbaseline
but who did not formally request to
be withdrawn. (NOTE. These were
included as expected in the com-
pliance calculations.) (†) Two pa-
tients who withdrew were sent and
completed the (end-of-study (EOS)
questionnaire as they had used
the systems for some time. ECOG
PS, Eastern Cooperative Oncology
Group performance status; EORTC-
QLQ-C30, European Organization
for the Research and Treatment of
Cancer Quality of Life Questionnaire
C30; PIS, Patient Information Sheet;
PRO-CTCAE, Patient Reported Out-
comes version of the Common Ter-
minology Criteria for Adverse Events.
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TABLE 1. Demographic Characteristics of the Study Population
Characteristic
Overall
(N 5 249)
Internet
(n 5 196)
IVRS
(n 5 43)
Missinga
(n 5 10)
Mean age, years (SD) 62.6 (13.4) 60.8 (13.7) 70.0 (9.9) 66.6 (8.4)
Gender
Male 128 (51.4) 99 (50.5) 23 (53.5) 6 (60.0)
Female 121 (48.6) 97 (49.5) 20 (46.5) 4 (40.0)
Marital Status
Married/civil partnership 173 (69.5) 138 (70.4) 30 (69.8) 5 (50.0)
Cohabiting 17 (6.8) 16 (8.2) 1 (2.3) 0 (—)
Separated/divorced 16 (6.4) 11 (5.6) 2 (4.7) 3 (30.0)
Widowed 14 (5.6) 6 (3.1) 6 (14.0) 2 (20.0)
Single 29 (11.6) 25 (12.8) 4 (9.3) 0 (—)
Employment
Full time 47 (18.9) 43 (21.9) 3 (7.0) 1 (10.0)
Part time 25 (10.0) 23 (11.7) 1 (2.3) 1 (10.0)
Unable 42 (16.9) 34 (17.3) 7 (16.3) 1 (10.0)
Retired 124 (49.8) 86 (43.9) 31 (72.1) 7 (70.0)
Unemployed, not looking 5 (2.0) 5 (2.6) 0 (—) 0 (—)
Unemployed, looking 1 (0.4) 0 (—) 1 (2.4) 0 (—)
Other 5 (2.0) 5 (2.6) 0 (—) 0 (—)
Education
Basic school level 93 (37.3) 64 (32.7) 23 (53.5) 6 (60.0)
Higher education (eg, A level)b 61 (24.5) 51 (26.0) 8 (18.6) 2 (20.0)
Degree level 95 (38.2) 81 (41.3) 12 (27.9) 2 (20.0)
Study group
Chemotherapy 43 (17.3) 37 (18.9) 6 (14.0) 0 (—)
Targeted agents 46 (18.5) 40 (20.4) 5 (11.6) 1 (10.0)
Hormone therapy 43 (17.3) 26 (13.3) 13 (30.2) 4 (40.0)
Radiotherapy 43 (17.3) 34 (17.3) 8 (18.6) 1 (10.0)
Surgery 42 (16.9) 36 (18.4) 4 (9.3) 2 (20.0)
ECOG PS 2-3 32 (12.9) 23 (11.7) 7 (16.3) 2 (20.0)
Disease group
Breast 57 (22.9) 45 (23.0) 8 (18.6) 4 (40.0)
Colorectal 39 (15.7) 35 (17.9) 3 (7.0) 1 (10.0)
Prostate 33 (13.3) 19 (9.7) 12 (27.9) 2 (20.0)
Leukemia 15 (6.0) 13 (6.6) 2 (4.7) 0 (—)
Myeloma 13 (5.2) 10 (5.1) 3 (7.0) 0 (—)
Lung 12 (4.8) 6 (3.1) 5 (11.6) 1 (10.0)
Renal 12 (4.8) 11 (5.6) 1 (2.3) 0 (—)
Head and neck 11 (4.4) 10 (5.1) 1 (2.3) 0 (—)
Rectal 10 (4.0) 9 (4.6) 1 (2.3) 0 (—)
Ovarian 9 (3.6) 6 (3.1) 3 (7.0) 0 (—)
Lymphoma 9 (3.6) 8 (4.1) 0 (—) 1 (10.0)
Pancreas 7 (2.8) 7 (3.6) 0 (—) 0 (—)
Bladder 6 (2.4) 5 (2.6) 1 (2.3) 0 (—)
(continued on following page)
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(10 patients when completing the PRO-CTCAE and 6 when
completing the EORTC), and 1 patient who preferred IVRS
and 3 who preferred the Internet used the opposite system
more frequently. Questionnaire completion was quicker on
the Internet (PRO-CTCAE median time, 3.0 minutes;
interquartile range [IQR], 2.0 to 4.0 minutes; EORTC
median time, 6.0 minutes; IQR, 4.0 to 8.0 minutes)
compared with IVRS (PRO-CTCAE median time, 7.0
minutes; IQR, 6.1 to 13.6 minutes; EORTC median time,
14.5 minutes; IQR, 13.5 to 15.9 minutes).
Attrition and Compliance
At week 12, 92.4% of participants (230 of 249) remained
on study, with 6 deaths and 13 active withdrawals (5.2%; 5
in week 1, 7 by week 5, and 1 in week 10). Five patients
who withdrew were receiving hormone therapy and 8 were
across the other treatment groups (ECOG/targeted/radio-
therapy, n 5 2; chemotherapy/surgery, n 51). Withdrawal
reasons included the time required to participate (n 5 2),
being unwell (n 5 2), stopped treatment (n 5 1), and
computer problems (n 5 2). Eighteen participants were
classified as passive withdrawals (7.2%), having not
completed any electronic questionnaires postbaseline.
Overall combined compliance for both systems was
74.9% for PRO-CTCAE (completed at 2,301 of 3,074
timepoints) and 79.1% for EORTC (completed at 749 of
947 timepoints). Table 2 lists compliance at each timepoint
split by gender, system, study group, and age. Individual
timepoint compliance (Figs 2A and 2B) shows more than
60% compliance throughout. Completions per participant
illustrates that 46.1% (106 of 230) completed 13 or more
PRO-CTCAE questionnaires, more than 80% (185 of 230)
completed 8 or more, and 59.1% (136 of 230) completed
the maximum 4 EORTC questionnaires (Figs 2C and 2D).
Compliance was higher in chemotherapy patients, with
week 12 cumulative rates of 85.3% and 90.4% for PRO-
CTCAE and EORTC, respectively (Table 2). Surgical par-
ticipants had the lowest PRO-CTCAE compliance (baseline,
88.1%; week 12 cumulative, 67.3%). ECOG participants
had lower EORTC compliance (baseline, 93.8%; month 3
cumulative, 68.7%).
Men and women had fairly similar compliance at each
timepoint (Table 2). PRO-CTCAE compliance was slightly
higher in the age group $ 60 years (week 12 cumulative,
78.5%) compared with the younger age group # 59 years
(week 12 cumulative, 68.9%). In contrast, EORTC com-
pliance was relatively similar at each timepoint.
PRO-CTCAE compliance fluctuated on both systems, but
cumulative compliance was similar (IVRS, 74.5%; Internet,
76.7%). In contrast, EORTC compliance was higher on
IVRS (cumulative month 3 IVRS, 85.6%; Internet, 79.8%);
however, the number of IVRS users was small.
Patient and Staff Feedback
EOS questionnaires were completed by 192 (82.8%) of 232
patients (Internet, n 5 157; IVRS, n 5 35). Among non-
responders (n 5 40), 20 had not completed any electronic
PRO-CTCAE questionnaires postbaseline (ie, passive
withdrawers; IVRS, n 5 3; Internet, n 5 17) and 20 had
engaged postbaseline (IVRS, n 5 4; Internet, n 5 16).
Almost all patients found the system(s) easy to use (IVRS,
n 5 35 [100%]; Internet, n 5 156 [98.1%]) and access
(IVRS, n 5 32 [94.1%]; Internet, n 5 148 [93.1%]), felt
prepared post-training (IVRS, n5 35 [100%]; Internet, n5
153 [96.8%]), and more than 80% of all patients (151
of 188) were happy completing weekly questionnaires.
Qualitative comments echoed this usability. Time to
complete was “about right” (IVRS, n 5 29 [82.9%]; In-
ternet, n5 157 [99.4%]), although 6 IVRS users felt it was
slow or took “too long”. Approximately one third (62 of 184;
33.7%) reported missing a week mainly because of illness
(n5 21) or forgetting (n5 24). Fourteen hormone therapy
patients (14 of 29; 48.3%) found few of the symptom
questions to be relevant to them.
Staff surveys (32 of 50; 64%) indicated positive views about
regular/weekly symptom reporting. Despite some concerns
over resources and the time needed to review data, the
TABLE 1. Demographic Characteristics of the Study Population (continued)
Characteristic
Overall
(N 5 249)
Internet
(n 5 196)
IVRS
(n 5 43)
Missinga
(n 5 10)
Gastric 6 (2.4) 5 (2.6) 1 (2.3) 0 (—)
Anal 3 (1.2) 3 (1.5) 0 (—) 0 (—)
Esophageal 3 (1.2) 1 (0.5) 2 (4.7) 0 (—)
Hepatocellular 2 (0.8) 2 (1.0) 0 (—) 0 (—)
Cholangiocarcinoma 2 (0.8) 1 (0.5) 0 (—) 1 (0.5)
NOTE. Data are given as No. (%), unless otherwise noted.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; IVRS, interactive voice response system; SD, standard deviation.
aThe system uptake reported is the system used most often during the study period. The most commonly used system was missing
from 9 participants who did not complete any questionnaires and 1 patient who had an even split between IVRS and Internet usage.
bAdvanced level qualification in the United Kingdom undertaken in school or college.
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benefit for auditing symptoms and directing consultations
and in clinical trials was emphasized.
System Testing
During the 17-month study, 3,170 questionnaires were
completed (2,413 PRO-CTCAE questionnaires and 757
EORTC questionnaires) and proportionately few issues were
recorded—38 patient-related and 69 system-related is-
sues. Notable system issues included reminder problems
(n 5 20), information technology/server issues (n 5 7)
affecting access or auto-emails, completion report is-
sues (n 5 12), and some technical difficulties (Internet,
n 5 11; IVRS, n 5 8). Overall downtime was not systemat-
ically recorded, but isolated incidences were experienced.
Patient issues included initial access problems (n 5 19),
completion queries (n5 8), and lost/forgotten username and/
or password (n 5 6). The PRO database was combined
successfully with the standard clinical trial database with only
a single issue during the data retrieval/combining process.
DISCUSSION
To our knowledge, this is the first study illustrating the
feasibility and acceptability of an electronic system to
collect both self-reported PRO-CTAE and HRQOL data from
a diverse sample of United Kingdom patients with cancer.
The results demonstrate patient willingness, low attrition
(5.2%; 13 of 249 active withdrawals), and high compliance
(approximately 60% to 70% week 12; cumulative, ap-
proximately 75% to 80%). Most participants preferred the
Internet, but approximately 17% of those who were older
used IVRS, indicating an that alternative mode was de-
sirable. Combining PRO data with the clinical trial database
worked effectively with few system issues recorded. This
approach is therefore recommended and a comparative
evaluation is now required.
The 47.9% recruitment rate is lower than the 70% uptake
rate routinely observed in PRO studies,11 but is encour-
aging compared with the 31% to 64% uptake rate in mailed
cancer surveys.26 Target participants included various di-
agnoses, which made robust interpretation of any differ-
ences between cancer groups challenging as a result of
small frequencies. Disease site was not associated with
the rate of consent for the study; however, uptake was
specifically low in some groups (eg, prostate and hor-
mone therapy). Therefore, the study findings cannot be
generalized to all cancer populations and may not reflect
TABLE 2. Cumulative Compliance Over Time
Questionnaire Overall
Gender System
Study Group
Age, Years
Male Female IVRS Internet Chemotherapy
Targeted
Agents
Hormone
Therapy Radiotherapy Surgery
ECOG PS
2-3 £ 59 ‡ 60
PRO-CTCAE
Baseline 93.2 93.0 93.4 95.3 96.9 100.0 93.5 86.0 97.7 88.1 93.8 95.7 91.7
Week 1 86.6 85.7 87.4 85.7 90.0 95.3 85.9 87.8 90.7 74.7 83.9 87.4 86.0
Week 2 84.0 83.4 84.6 80.8 87.5 93.0 81.2 85.1 92.1 70.2 81.5 81.8 85.3
Week 3 82.2 81.9 82.5 79.5 85.3 90.6 77.7 85.6 90.5 70.3 77.0 78.1 84.6
Week 4 80.3 80.4 80.2 79.6 82.8 88.3 73.8 82.8 89.0 72.3 74.3 76.3 82.7
Week 5 79.3 79.6 79.1 78.9 81.7 87.5 73.4 82.2 87.6 71.1 73.1 74.9 82.1
Week 6 78.9 79.3 78.4 76.9 81.3 88.2 72.7 81.4 85.9 71.3 72.2 73.9 81.9
Week 7 78.3 78.5 78.0 77.0 80.5 88.2 72.5 80.4 84.3 70.9 71.8 72.5 81.8
Week 8 77.0 77.1 76.9 77.3 78.9 86.4 70.9 79.7 82.8 69.9 71.1 71.1 80.6
Week 9 76.4 76.8 76.0 77.1 78.2 85.8 70.7 79.6 81.4 69.5 70.1 70.6 80.0
Week 10 76.0 76.4 75.6 76.5 77.8 86.4 70.5 79.6 80.0 68.6 69.5 70.3 79.5
Week 11 75.5 76.0 74.9 75.3 77.3 85.9 69.9 79.1 79.2 68.1 68.9 69.7 79.0
Week 12 74.9 75.4 74.3 74.5 76.7 85.3 69.5 78.7 78.0 67.3 69.0 68.9 78.5
EORTC
Baseline 96.0 95.3 96.7 100.0 99.0 100.0 95.7 93.0 100.0 92.9 93.8 97.8 94.9
Month 1 88.5 88.0 89.0 92.7 90.3 95.3 85.7 89.0 94.0 86.6 77.4 89.6 87.8
Month 2 84.5 84.5 84.6 90.1 85.7 95.2 80.7 85.0 88.8 81.1 73.0 85.6 83.9
Month 3 79.1 79.6 78.6 85.6 79.8 90.4 74.9 77.8 83.1 76.5 68.7 79.2 79.0
NOTE. Data are given as percentages, unless otherwise noted.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; EORTC, European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-C30; IVRS, interactive voice response system; PRO-CTCAE, Patient Reported Outcomes version of the Common Terminology
Criteria for Adverse Events.
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the compliance/views of specific cancer groups who were
under-represented in this study. Patients required Inter-
net access or a touch-tone telephone, which excluded
some patients or those not confident with technology. In
a clinical trial setting, offering paper-based PROs should
continue, although this may diminish as Internet use in-
creases. Those who declined tended to be older,19 but
reasons focused on being too busy/overwhelmed with
treatment. This study provided limited personal benefit
beyond altruism; therefore, if electronic PRO reporting
was integrated into treatment trials, uptake could be
higher. Basch et al18,27 report higher uptake, although
their approach included clinic-based computer comple-
tions. Future trials, combining remote/home-based
completions with clinic-based completions may optimize
compliance.
Compliance overall was high (approximately 60% to 70% at
week 12; cumulative, approximately, 75% to 80%) and
higher still in chemotherapy patients regularly going to
the hospital for treatment reviews. PRO-CTCAE items
chosen were particularly applicable to chemotherapy-
related symptoms. Lower weekly compliance for surgical
patients may be a result of the intense recovery period
immediately postsurgery and less frequent review post-
surgery. Some clinical trials that included paper-based
QOL measures have observed higher compliance (75% at
6 months28), but the current study had more intense fre-
quency (weekly/every 4 weeks). In an active clinical trial,
compliance may be higher because of patient selection,
trial-related incentives, and item relevance.29 Basch et al27
reported 92% cumulative compliance for home PRO-
CTCAE reporting in trial patients, but 14.7% of question-
naires were collected via a coordinator directly ringing
patients.
Despite most participants choosing to use the Internet,
some older patients preferred the IVRS.27 An alternative
real-time method is desirable if the purpose of collection is
tracking symptoms/AEs, whereas if the aim is obtaining
HRQOL outcomes, paper-based alternatives may suffice.
Overall compliance did not differ across systems, but dif-
ferent patterns were observed, potentially influenced by the
order of presentation: EORTC was presented first on the
IVRS at the once every 4 weeks intervals (explaining higher
EORTC IVRS compliance), whereas Internet users had to
proactively choose both questionnaires. Furthermore,
completions on the Internet were quicker, which may be
a result of the systems themselves (ie, IVRS required the
questions/answers to be read out at a comprehensible
speed), but it may also reflect the younger, more educated
Internet users.
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FIG 2. Compliance and number of completions per participant for PRO-CTCAE (Patient Reported Outcomes version of the Common Terminology Criteria for
Adverse Events) and EORTC (European Organization for Research and Treatment of Cancer QLQ-C30) questionnaires. (A) PRO-CTCAE weekly compliance
across the 12-week study period. (B) EORTC compliance every 4 weeks across the 12-week study period. (C) Total number of PRO-CTCAE completions per
participant. (D) Total number of EORTC completions per participant.
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Patient feedback was positive, finding the systems accept-
able and problem free. Most issues were related to initial
queries or access problems and were quickly resolved.
Reasons for noncompletion were a result of being unwell or
forgetting, rather than negativity about the systems.
The systems were only available in English, which is
a limitation that should be addressed in future work.
Furthermore, the general oncology setting influenced how
the study was presented (focusing on system testing rather
than on the value of collecting PROs in trials) and potentially
affected uptake and compliance. The definition of baseline
differed to what would be done in a formal clinical trial
setup: A lenient baseline PRO-CTCAE/HRQOL completion
(up to 3 days postregistration) was used, rather than
prerandomization, as in many clinical trials.
The study highlights implementation considerations for
future actual clinical trial use, including the need for
a serious AE (or suspected unexpected serious adverse
reaction) alert system, clinicians directly receiving symptom
summary reports or alerts, and a function for individual
symptom reporting or adding other free-text symptoms.
Some of the considerations also relate to concerns voiced
regarding the ethics of PRO data in clinical trials and the
timescale of data review.30 Using an electronic PRO system
with automated alerts helps with the timely management of
these issues compared with paper-based methods, but
creates new training needs for trial staff.31 Furthermore,
electronic data collection requires continuous assessment
to ensure that information technology systems and in-
frastructuremeet clinical trial regulation andMedicines and
Healthcare products Regulatory Agency and European
Medicines Agency requirements.32
In conclusion, routine collection of PRO data in cancer
clinical trials is increasingly important. This study illustrates
the feasibility and patient acceptance of electronic PROs
during treatment and incorporating PRO data into clinical
trials. Additional exploration of this system is warranted
where PROs are combined with other trial data—alongside
traditional approaches—to improve data quality and patient
safety.
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